Fasenra

RSS

benralizumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Fasenra is an asthma medicine used to treat adults with a particular type of asthma called eosinophilic asthma. It is used as an additional treatment in adults with severe asthma that is not adequately controlled by a combination of high-dose inhaled corticosteroids plus medicines called long-acting beta-agonists. Fasenra contains the active substance benralizumab.

This EPAR was last updated on 25/05/2023

Authorisation details

Product details
Name
Fasenra
Agency product number
EMEA/H/C/004433
Active substance
Benralizumab
International non-proprietary name (INN) or common name
benralizumab
Therapeutic area (MeSH)
Asthma
Anatomical therapeutic chemical (ATC) code
R03DX10
Publication details
Marketing-authorisation holder
AstraZeneca AB
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
08/01/2018
Contact address

151 85 Sodertalje
Sweden

Product information

15/09/2022 Fasenra - EMEA/H/C/004433 - R/0044

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Fasenra is indicated as an add on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long acting β agonists.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating
1 rating
4 ratings